ASCO GU 2023 Prostate Cancer - Results from #20

Viewing 21-40 of 95 articles

ASCO GU 2023: Impact of 68Ga-PSMA PET/CT in Patients with mCRPC Treated with Enzalutamide

ASCO GU 2023: Effect of Body Weight on Standardized Uptake Values on 18F-DCFPyL PSMA PET/CT in Patients with Prostate Cancer

ASCO GU 2023: Niraparib with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Gene Alterations: Second Interim Analysis of MAGNITUDE

ASCO GU 2023: Clinical Implementation of 177Lu-PSMA-617 at a Major Academic Center: Initial Experiences

ASCO GU 2023: Developing a Novel Patient-Reported Outcome Measure for Patients with Prostate Cancer Receiving Radionuclide Therapy: The FACT-RNT

ASCO GU 2023: AlphaBet: A Phase I/II Trial Evaluating the Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in Patients with mCRPC

ASCO GU 2023: First-in-Class Oral Innate Immune Activator BXCL701 Combined with Pembrolizumab in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC) of Small Cell Neuroendocrine (SCNC) Phenotype: Phase 2a Final Results

ASCO GU 2023: Randomized, Double-Blinded Phase II Study of Ketoconazole, Hydrocortisone, and Anti-PSMA Antibody J591 Labeled with 177Lu or 111In in Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0 CRPC)

ASCO GU 2023: A Phase I/II Dose-Escalation Study of Fractionated 225Ac-J591 for Progressive mCRPC in Patients with Prior Treatment with 177Lu-PSMA

ASCO GU 2023: 68GaPSMA-11 PET/CT to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and PSMA Response

ASCO GU 2023: Dosing, Safety, and Pharmacokinetics of Combination Therapy with Darolutamide, ADT, and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in the ARASENS Study

ASCO GU 2023: Detection of True Positive M1 Lesions by 18F-rhPSMA-7.3 PET in Newly Diagnosed Prostate Cancer: Results from the Phase 3 Prospective LIGHTHOUSE Study

ASCO GU 2023: Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study

ASCO GU 2023: Results of a Multicenter, Randomized, Phase 3 Trial of Trimodality Therapy with I-125 Brachytherapy, External Beam Radiation Therapy, and Long- Versus Short-Term ADT for Localized High-Risk Prostate Cancer (TRIP/TRIGU0907)

ASCO GU 2023: Efficacy and Safety of Abiraterone Acetate plus Prednisone and ADT +/- Docetaxel in Older Patients (≥70 Years), with De Novo mCSPC, Compared to Younger Patients (70 Years): The PEACE-1 Trial

ASCO GU 2023: PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis

ASCO GU 2023: Treatment Combinations for Patients Starting Androgen-Deprivation Therapy: Building on Recent Victories

ASCO GU 2023: 10-Year Efficacy and Co-Morbidity Outcomes of a Phase III Randomised Trial of Conventional vs. Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP; CRUK/06/016)

ASCO GU 2023: New Targets, New Concepts for Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2023: How to Best Use Current Drugs: Treatment Sequencing and Combinations for Metastatic Castration-Resistant Prostate Cancer

1
2
3
4
5